Influence of Bleeding Risk on Outcomes of Radial and Femoral Access for Percutaneous Coronary Intervention: An Analysis From the GLOBAL LEADERS Trial.


Journal

The Canadian journal of cardiology
ISSN: 1916-7075
Titre abrégé: Can J Cardiol
Pays: England
ID NLM: 8510280

Informations de publication

Date de publication:
01 2021
Historique:
received: 06 11 2019
revised: 27 01 2020
accepted: 27 01 2020
pubmed: 26 5 2020
medline: 16 6 2021
entrez: 26 5 2020
Statut: ppublish

Résumé

Radial artery access has been shown to reduce mortality and bleeding events, especially in patients with acute coronary syndromes. Despite this, interventional cardiologists experienced in femoral artery access still prefer that route for percutaneous coronary intervention. Little is known regarding the merits of each vascular access in patients stratified by their risk of bleeding. Patients from the Global Leaders trial were dichotomized into low or high risk of bleeding by the median of the PRECISE-DAPT score. Clinical outcomes were compared at 30 days. In the overall population, there were no statistical differences between radial and femoral access in the rate of the primary end point, a composite of all-cause mortality, or new Q-wave myocardial infarction (MI) (hazard ratio [HR] 0.70, 95% confidence interval [CI] 0.42-1.15). Radial access was associated with a significantly lower rate of the secondary safety end point, Bleeding Academic Research Consortium (BARC) 3 or 5 bleeding (HR 0.55, 95% CI 0.36-0.84). Compared by bleeding risk strata, in the high bleeding score population, the primary (HR 0.47, 95% CI 0.26-0.85; P = 0.012; P Our findings suggest that the outcomes of mortality or new Q-wave MI and BARC 3 or 5 bleeding favour radial access in patients with a high, but not those with a low, risk of bleeding. Because this was not a primary analysis, it should be considered hypothesis generating.

Sections du résumé

BACKGROUND
Radial artery access has been shown to reduce mortality and bleeding events, especially in patients with acute coronary syndromes. Despite this, interventional cardiologists experienced in femoral artery access still prefer that route for percutaneous coronary intervention. Little is known regarding the merits of each vascular access in patients stratified by their risk of bleeding.
METHODS
Patients from the Global Leaders trial were dichotomized into low or high risk of bleeding by the median of the PRECISE-DAPT score. Clinical outcomes were compared at 30 days.
RESULTS
In the overall population, there were no statistical differences between radial and femoral access in the rate of the primary end point, a composite of all-cause mortality, or new Q-wave myocardial infarction (MI) (hazard ratio [HR] 0.70, 95% confidence interval [CI] 0.42-1.15). Radial access was associated with a significantly lower rate of the secondary safety end point, Bleeding Academic Research Consortium (BARC) 3 or 5 bleeding (HR 0.55, 95% CI 0.36-0.84). Compared by bleeding risk strata, in the high bleeding score population, the primary (HR 0.47, 95% CI 0.26-0.85; P = 0.012; P
CONCLUSIONS
Our findings suggest that the outcomes of mortality or new Q-wave MI and BARC 3 or 5 bleeding favour radial access in patients with a high, but not those with a low, risk of bleeding. Because this was not a primary analysis, it should be considered hypothesis generating.

Identifiants

pubmed: 32450057
pii: S0828-282X(20)30178-1
doi: 10.1016/j.cjca.2020.01.029
pii:
doi:

Types de publication

Journal Article Multicenter Study Randomized Controlled Trial Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

122-130

Informations de copyright

Copyright © 2020 Canadian Cardiovascular Society. Published by Elsevier Inc. All rights reserved.

Auteurs

Chao Gao (C)

Department of Cardiology. Xijing Hospital, Xi'an, China; Department of Cardiology, Radboud University, Nijmegen, The Netherlands; Department of Cardiology, National University of Ireland, Galway, Ireland.

Piotr Buszman (P)

Centre for Cardiovascular Research and Development, American Heart of Poland, Kostkowice, Poland; Andrzej Frycz Modrzewski Krakow University, Krakow, Poland.

Paweł Buszman (P)

Centre for Cardiovascular Research and Development, American Heart of Poland, Ustron, Poland.

Ply Chichareon (P)

Division of Cardiology, Department of Internal Medicine, Prince of Songkla University, Songkhla, Thailand.

Rodrigo Modolo (R)

Cardiology Division. Department of Internal Medicine, University of Campinas, Campinas, Brazil.

Scot Garg (S)

Department of Cardiology, Royal Blackburn Hospital, Blackburn, UK.

Kuniaki Takahashi (K)

Department of Cardiology, Amsterdam University Medical Center, Amsterdam, The Netherlands.

Hideyuki Kawashima (H)

Department of Cardiology, Amsterdam University Medical Center, Amsterdam, The Netherlands; Department of Cardiology, National University of Ireland, Galway, Ireland.

Rutao Wang (R)

Department of Cardiology. Xijing Hospital, Xi'an, China; Department of Cardiology, Radboud University, Nijmegen, The Netherlands; Department of Cardiology, National University of Ireland, Galway, Ireland.

Chun Chin Chang (CC)

Department of Cardiology, Radboud University, Nijmegen, The Netherlands.

Norihiro Kogame (N)

Department of Cardiology, Amsterdam University Medical Center, Amsterdam, The Netherlands.

Mariusz Tomaniak (M)

Erasmus Medical Center, Erasmus University, Rotterdam, The Netherlands.

Masafumi Ono (M)

Department of Cardiology, Amsterdam University Medical Center, Amsterdam, The Netherlands; Department of Cardiology, National University of Ireland, Galway, Ireland.

Hironori Hara (H)

Department of Cardiology, Amsterdam University Medical Center, Amsterdam, The Netherlands; Department of Cardiology, National University of Ireland, Galway, Ireland.

Ton Slagboom (T)

Onze Lieve Vrouwe Gasthuis, Amsterdam, The Netherlands.

Adel Aminian (A)

Division of Cardiology, Centre Hospitalier Universitaire de Charleroi, Charleroi, Belgium.

Christoph Kurt Naber (CK)

Department of Cardiology and Angiology, Elisabeth-Krankenhaus Essen, Essen, Germany.

Didier Carrie (D)

Cardiology B Department, CHU Toulouse, Hôpital Rangueil, Toulouse, France.

Christian Hamm (C)

Kerckhoff Heart Center, Bad Nauheim, Germany.

Philippe Gabriel Steg (PG)

Hôpital Bichat, l'Assistance Publique-Hôpitaux de Paris, Université Paris-Diderot, Paris, France; Royal Brompton Hospital, Imperial College, London, United Kingdom.

Yoshinobu Onuma (Y)

Erasmus Medical Center, Erasmus University, Rotterdam, The Netherlands; Department of Cardiology, National University of Ireland, Galway, Ireland.

Robert-Jan van Geuns (RV)

Department of Cardiology, Radboud University, Nijmegen, The Netherlands.

Patrick W Serruys (PW)

National Heart and Lung Institute, Imperial College London, London, United Kingdom; Department of Cardiology, National University of Ireland, Galway, Ireland. Electronic address: patrick.w.j.c.serruys@gmail.com.

Aleksander Zurakowski (A)

Andrzej Frycz Modrzewski Krakow University, Krakow, Poland; American Heart of Poland, Chrzanow, Poland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH